Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 3:08 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 217–240 of 5,229 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Control/Placebo group Clear all

Conditions: Respiratory Syncytial Virus (RSV)
Interventions: Investigational RSV vaccine MV-012-968 (Dosage 1), Investigational RSV vaccine MV-012-968 (Dosage 2), Investigational RSV vaccine MV-012-968 (Dosage 3; single-dose), Investigational RSV vaccine MV-012-968 (Dosage 3; two-dose), Placebo (single-dose), Placebo (two-dose); Biological · Other
Lead sponsor: Meissa Vaccines, Inc.; Industry
Eligibility: 6 Months to 36 Months
Enrollment: 63 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 12
States / cities: Phoenix, Arizona • La Mesa, California • Atlanta, Georgia + 9 more

Conditions: Idiopathic Thrombocytopenic Purpura
Interventions: Eltrombopag, Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 1 Year to 17 Years
Enrollment: 92 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 4
States / cities: Los Angeles, California • St. Petersburg, Florida • Brooklyn, New York + 1 more

Conditions: Systemic Lupus Erythematosus (SLE)
Interventions: Placebo, Dapirolizumab pegol (DZP); Drug
Lead sponsor: UCB Biopharma S.P.R.L.; Industry
Eligibility: 18 Years and older
Enrollment: 182 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 25
States / cities: Birmingham, Alabama • El Cajon, California • Huntington Beach, California + 21 more

Conditions: Niemann-Pick Type C Disease, GM1 Gangliosidosis, GM2 Gangliosidosis
Interventions: AZ-3102, Placebo; Drug
Lead sponsor: Azafaros B.V.; Industry
Eligibility: 4 Years and older
Enrollment: 147 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 5
States / cities: Oakland, California • Minneapolis, Minnesota • Rochester, Minnesota + 2 more

Conditions: Lactation
Interventions: Similac Prenatal Vitamin soft-gel capsule, Placebo (soybean oil and dl-alpha-tocopheryl acetate); Dietary Supplement
Lead sponsor: Abbott Nutrition; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 89 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 6
States / cities: Indianapolis, Indiana • Dayton, Ohio • Kettering, Ohio + 3 more

Conditions: Postpartum Depression
Interventions: SAGE-217 15/20 mg Oral Solution, Placebo, SAGE 217 30 mg Capsules; Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 276 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 27
States / cities: Little Rock, Arkansas • Beverly Hills, California • Oceanside, California + 24 more

Conditions: Colitis, Ulcerative
Interventions: VTX002, Placebo; Drug
Lead sponsor: Oppilan Pharma Ltd; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 213 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 19
States / cities: Garden Grove, California • Lancaster, California • San Diego, California + 16 more

Conditions: Healthy
Interventions: V330, Placebo; Biological
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years to 79 Years
Enrollment: 245 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 4
States / cities: Glendale, California • Hallandale, Florida • Hollywood, Florida + 1 more

Conditions: Malignant Neoplasm
Interventions: Dexamethasone, Placebo, Questionnaire, Quality-of-Life Assessment, Everolimus; Drug · Other
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 319
States / cities: Birmingham, Alabama • Kingman, Arizona • Fort Smith, Arkansas + 198 more

Conditions: Asthma
Interventions: BI 1744 CL; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 296 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2007
U.S. locations: 10
States / cities: Lakewood, California • Los Angeles, California • San Diego, California + 6 more

Conditions: Smoking ( Cigarette), Breastfeeding
Interventions: Breastfeeding promotion, Attention placebo control; Behavioral
Lead sponsor: State University of New York at Buffalo; Other
Eligibility: 18 Years and older · Female only
Enrollment: 280 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Respiratory Syncytial Virus Immunization, Human Metapneumovirus Immunization, Healthy Volunteers
Interventions: RSV+HMPV vaccine, Control Vaccine 3, Control Vaccine 4, Control Vaccine 2, Placebo, Control Vaccine 1; Biological · Other
Lead sponsor: Sanofi; Industry
Eligibility: 60 Years and older
Enrollment: 2,400 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 50
States / cities: Gadsden, Alabama • Vestavia Hills, Alabama • Huntington Beach, California + 43 more

Conditions: Diabetes Mellitus, Type II, Diabetes Mellitus, Non Insulin Dependent
Interventions: Canagliflozin (JNJ-28431754), Sitagliptin, Placebo; Drug
Lead sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 451 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 30
States / cities: Birmingham, Alabama • Mesa, Arizona • Tucson, Arizona + 27 more

Conditions: Type 2 Diabetes
Interventions: dapagliflozin, placebo, metformin; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 79 Years
Enrollment: 389 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 111
States / cities: Bayou La Batre, Alabama • Birmingham, Alabama • Huntsville, Alabama + 107 more

Conditions: Multiple Sclerosis
Interventions: Laquinimod, Placebo, Avonex®; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 1,331 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 36
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 31 more

Conditions: NON-ALCOHOLIC STEATOHEPATITIS
Interventions: DA-1241, Sitagliptin, DA-1241 Placebo, Sitagliptin Placebo; Drug
Lead sponsor: NeuroBo Pharmaceuticals Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 109 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 18
States / cities: Coronado, California • Montclair, California • Panorama City, California + 12 more

Conditions: Multiple Sclerosis
Interventions: Teriflunomide, Placebo (for Teriflunomide), Interferon-β; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 118 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: Healthy Adult Premenopausal Female Volunteers
Interventions: ITCA 650 20/60 mcg/day, ITCA placebo, ITCA placebo, ITCA 650 20/60 mcg/day; Drug
Lead sponsor: Intarcia Therapeutics; Industry
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 2
States / cities: Miami, Florida • Orlando, Florida

Conditions: Dementia, Behavior Problems
Interventions: TREA (Treatment Routes for Exploring Agitation), Placebo Control Group; Behavioral
Lead sponsor: National Institute on Aging (NIA); NIH
Eligibility: 60 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 1
States / cities: Rockville, Maryland

Conditions: Pulmonary Arterial Hypertension, Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease, Pulmonary Hypertension
Interventions: sildenafil; Drug
Lead sponsor: University of California, Los Angeles; Other
Eligibility: Not listed
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Chronic Obstructive Pulmonary Disease (COPD)
Interventions: Placebo, Tozorakimab; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 40 Years to 130 Years
Enrollment: 1,454 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 57
States / cities: Birmingham, Alabama • Decatur, Alabama • Sheffield, Alabama + 51 more

Conditions: Anemia
Interventions: Sotatercept, Placebo; Biological
Lead sponsor: Celgene; Industry
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2016
U.S. locations: 24
States / cities: Azusa, California • Glendale, California • La Mesa, California + 16 more

Conditions: Diabetes Mellitus, Type 2, Osteoporosis
Interventions: Denosumab 60 mg/ml [Prolia], Placebo; Drug · Other
Lead sponsor: Mishaela Rubin; Other
Eligibility: 50 Years to 90 Years · Female only
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: New York, New York

Conditions: Crohn's Disease, IBD
Interventions: Brazikumab low dose, Brazikumab high dose, Humira®, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 89 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 38
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Lancaster, California + 31 more

Search by objective public record fields.

Safety and Immunogenicity of an Intranasal Vaccine for Respiratory Syncytial Virus in Seronegative Children 6-36 Months

Study of a New Medication for Childhood Chronic Immune Thrombocytopenia (ITP), a Blood Disorder of Low Platelet Counts That Can Lead to Bruising Easily, Bleeding Gums, and/or Bleeding Inside the Body.

A Phase 2 Efficacy and Safety Study of Dapirolizumab Pegol (DZP) in Systemic Lupus Erythematosus

A Study to Evaluate the Safety and Efficacy of Oral Nizubaglustat (AZ-3102) in Late-infantile and Juvenile Forms of Niemann-Pick Type C Disease, GM1 Gangliosidosis or GM2 Gangliosidosis

Lactation Fortification Study

A Study to Evaluate SAGE-217 in Participants With Severe Postpartum Depression

VTX002 Versus Placebo for the Treatment of Moderately to Severely Active Ulcerative Colitis

A Study of V330 in Healthy Younger (18 to 49 Years Inclusive) and Healthy Older (60 to 79 Years Inclusive) Participants (V330-001)

Dexamethasone in Reducing Everolimus-Induced Oral Stomatitis in Patients With Cancer

Efficacy and Safety of 4 Weeks of Treatment With Inhaled BI 1744 CL in Patients With Asthma

Prevention of Postpartum Smoking Relapse and Related Health Consequences by Breastfeeding Promotion

Phase 1/2 Study of Respiratory Syncytial Virus and Human Metapneumovirus (RSV+HMPV) Vaccine Candidate in Adults 60 Years of Age and Older

An Efficacy, Safety, and Tolerability Study of Canagliflozin (JNJ-28431754) in Patients With Type 2 Diabetes

A Trial of BMS-512148 in Patients With Type 2 Diabetes Mellitus

BRAVO Study: Laquinimod Double-blind Placebo-controlled Study in Participants With Relapsing-Remitting Multiple Sclerosis (RRMS) With a Rater Blinded Reference Arm of Interferon β-1a (Avonex®)

Study to Evaluate the Efficacy and Safety of DA-1241 in Subjects With Presumed NASH

Phase II Study of Teriflunomide as Adjunctive Therapy to Interferon-beta in Subjects With Multiple Sclerosis

Study of the Effect of ITCA 650 on the PK/PD of Oral Contraceptive in Healthy Female Subjects

Treatment Routes for Exploring Agitation

Pulmonary Hypertension Secondary to Idiopathic Pulmonary Fibrosis And Treatment With Sildenafil

Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations

A Phase 2a Study To Evaluate The Pharmacokinetics, Safety, Efficacy, Tolerability, And Pharmacodynamics of Sotatercept (ACE-011) for the Correction of Anemia in Subjects With End-stage Renal Disease on Hemodialysis.

Therapy of the Skeletal Disease of Type 2 Diabetes With Denosumab

An Active and Placebo-Controlled Study of Brazikumab in Participants With Moderately to Severely Active Crohn's Disease